Alcohol Use DisorderMoCA/BEARNINCT04009707
Comparison of 2 Tests to Diagnose Cognitive Dysfunctions in Alcohol Disease
An observational study of Alcohol Use Disorder, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
The objective of this study is therefore to compare the results obtained with these two screening tests, using as gold standard the results obtained by the battery of neuropsychological reference tests. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alcohol Use Disorder
- What is being tested?
- MoCA (Montreal Cognitive Assessment) test and BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test
- How many people
- 90 participants
- Where
- 1 siteFrance
- Study dates
- 2 Nov 2017to 31 Dec 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: patients with alcoo use desorder
Who may be able to join
- patients with alcoo use desorder
- Patient cared for in the addictology department of the University Hospital of Nîmes
Who cannot join
- refusal to use the data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of 2 Tests for Screening for Cognitive Disorders (MoCA / BEARNI)
The objective of this study is therefore to compare the results obtained with these two screening tests, using as gold standard the results obtained by the battery of neuropsychological reference tests.
Read the detailed description
Recently, a new screening test for cognitive disorders was specifically developed for patients with UAS: BEARNI (Brief Evaluation of Alcohol-Related Neuropsychological Impairments). Since the BEARNI is presented as the reference test, the investigators have systematically proposed it to hospitalized patients, in combination with the usual check-up. In practice, at admission, patients were therefore given two screening tests, the MoCA and the BEARNI. In the event of an anomaly in at least one of these tests, a battery of confirmatory neuropsychological tests was performed.
- Conditions
- Alcohol Use Disorder
- Being tested
- MoCA (Montreal Cognitive Assessment) test, BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test
- Keywords
- MoCA, BEARNI
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MoCA (Montreal Cognitive Assessment) testOther
the MoCA questionnaire is used to assess cognitive disorders
BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) TestOther
This questionnaire is used to assess cognitive disorders
| Study group | Role | What they receive |
|---|---|---|
| patients with alcool use desorders | Patient cared for in the addictology department of the University Hospital of Nîmes Receives: Other: MoCA (Montreal Cognitive Assessment) test; Other: BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test |
What is being measured
The primary outcome is the main question the study is designed to answer.
sensitivity
comparison of the sensitivity of the 2 tests against the gold standard
Measured: Day 1 (only 1 time)
specificity
comparison of the specificity of the 2 tests against the gold standard
Measured: Day 1 (only 1 time)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jul 2019
- Study start2 Nov 2017
- Primary completion31 Dec 2018
- Study completion31 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04009707
- Sponsor's protocol ID
- Local/2017/PP-02
- Acronym
- MoCA/BEARNI
- Status last verified
- Jul 2019
- First submitted
- 1 Jul 2019
- Last updated
- 3 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Pelletier S, Alarcon R, Ewert V, Forest M, Nalpas B, Perney P. Comparison of the MoCA and BEARNI tests for detection of cognitive impairment in in-patients with alcohol use disorders. Drug Alcohol Depend. 2018 Jun 1;187:249-253. doi: 10.1016/j.drugalcdep.2018.02.026. Epub 2018 Apr 10.
PubMed 29684893
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of 2 Tests for Screening for Cognitive Disorders (MoCA / BEARNI)
- ClinicalTrials.gov ID
- NCT04009707
- Acronym / sponsor ID
- MoCA/BEARNI / Local/2017/PP-02
- Conditions
- Alcohol Use Disorder
- Keywords
- MoCA, BEARNI
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 2 Nov 2017 (actual)
- Primary completion
- 31 Dec 2018 (actual)
- Study completion
- 31 Dec 2018 (actual)
- First posted
- 5 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is therefore to compare the results obtained with these two screening tests, using as gold standard the results obtained by the battery of neuropsychological reference tests.
Detailed description
Recently, a new screening test for cognitive disorders was specifically developed for patients with UAS: BEARNI (Brief Evaluation of Alcohol-Related Neuropsychological Impairments). Since the BEARNI is presented as the reference test, the investigators have systematically proposed it to hospitalized patients, in combination with the usual check-up. In practice, at admission, patients were therefore given two screening tests, the MoCA and the BEARNI. In the event of an anomaly in at least one of these tests, a battery of confirmatory neuropsychological tests was performed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with alcool use desorders | – | Other: MoCA (Montreal Cognitive Assessment) test, Other: BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) TestPatient cared for in the addictology department of the University Hospital of Nîmes |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- patients with alcoo use desorder
Key inclusion criteria (2 listed)
- patients with alcoo use desorder
- Patient cared for in the addictology department of the University Hospital of Nîmes
Key exclusion criteria (1 listed)
- refusal to use the data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MoCA (Montreal Cognitive Assessment) testthe MoCA questionnaire is used to assess cognitive disorders | Other | patients with alcool use desorders |
| BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) TestThis questionnaire is used to assess cognitive disorders | Other | patients with alcool use desorders |
Primary outcome
sensitivity
Time frame: Day 1 (only 1 time)
comparison of the sensitivity of the 2 tests against the gold standard
specificity
Time frame: Day 1 (only 1 time)
comparison of the specificity of the 2 tests against the gold standard
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
- Results publication: PubMed 29684893Pelletier S, Alarcon R, Ewert V, Forest M, Nalpas B, Perney P. Comparison of the MoCA and BEARNI tests for detection of cognitive impairment in in-patients with alcohol use disorders. Drug Alcohol Depend. 2018 Jun 1;187:249-253. doi: 10.1016/j.drugalcdep.2018.02.026. Epub 2018 Apr 10.
Related trials for Alcohol Use Disorder
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alcohol Use Disorder, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
sensitivity (time frame: Day 1 (only 1 time)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04009707, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.